TRULICITY 1.5MG 4 PEN
Description Of TRULICITY 1.5MG 4 PEN
- Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
- in addition to other medicinal products for the treatment of diabetes.
No dose adjustment is required based on age
No dose adjustment is required in patients with mild, moderate, or severe renal impairment (eGFR < 90 to ≥ 15 mL/min/1.73 m2).
There is very limited experience in patients with end-stage renal disease (< 15 mL/min/1.73 m2), therefore Trulicity cannot be recommended in this population
No dose adjustment is required in patients with hepatic impairment.
The safety and efficacy of dulaglutide in children aged less than 18 years have not yet been established. No data are available.
Fertility, pregnancy, and lactation
There is no or limited amount of data on the use of dulaglutide in pregnant women. Studies in animals have shown reproductive toxicity. Therefore, the use of dulaglutide is not recommended during pregnancy.
It is unknown whether dulaglutide is excreted in human milk. A risk to newborns/infants cannot be excluded. Dulaglutide should not be used during breastfeeding.
The effect of dulaglutide on fertility in humans is unknown. In the rat, there was no direct effect on mating or fertility following treatment with dulaglutide
Overdose of TRULICITY 1.5MG 4 PEN
Effects of overdose with dulaglutide in clinical studies have included gastrointestinal disorders and hypoglycemia. In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.